TABLE 4.

Success rates by infection site in febrile episodes classified as clinically or microbiologically documented infection (ITT analysis)

Infection or infection site	No. of patients with successful result/total no. (%)
	Ciprofloxacin	Ceftazidime plus amikacin
Bacteremia	14/31 (45.1)	13 /29 (44.8)
Respiratory tract	3 /13 (23.1)	4 /18 (22.2)
Pneumonia	3 /11 (27.3)	2 /14 (14.3)
Skin or skin structure	6 /11 (54.5)	5 /10 (50)
Gastrointestinal tract	5 /7 (71.4)	4 /5 (80)
Urinary tract	2 /4 (50)	2 /3 (66.7)
Others	0/2 (0)
Total	30/68 (44.1)	28/65 (43.1)